查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602791

发炎治疗市场：按药物类别、适应症和用途分类 - 2025-2030 年全球预测

Anti-Inflammatory Therapeutics Market by Drug Class (Anti-inflammatory Biologics, Corticosteroids, Non-steroidal Anti-inflammatory Drugs ), Indication, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年发炎治疗市值为1,015.3亿美元，预计到2024年将达到1,038.5亿美元，复合年增长率为4.93%，到2030年将达到1,422.1亿美元。

发炎治疗市场包括减少发炎是关节炎、气喘和发炎性肠道疾病肠道疾病等许多疾病的通用途径。人口老化、慢性病盛行率上升以及人们对早期疗育发炎疾病益处的认识不断提高，推动了需求的激增。发炎治疗对于现代医学至关重要，其在药物、生技药品和生物相似药中的应用，最终用户范围从医院、诊所到研究机构。该市场的成长受到生物技术进步、新治疗方法的采用以及全球医疗基础设施投资增加的显着影响。个人化医疗和标靶治疗带来了有望提高疗效和减少副作用的新机会。在关键地区有利的法律规范和快速的医药品认证过程的支持下，生物製药产业仍然是创新和研究的沃土。儘管存在这些机会，但市场仍面临高昂的研发成本、严格的监管要求以及潜在的副作用等挑战，阻碍了市场进入和开拓。此外，来自学名药和替代药物的竞争威胁着市场的扩张。为了实现可持续的业务成长，公司应专注于基于人工智慧的药物发现和生物相似药开发等创新方法。此外，建立策略联盟和投资新兴国家可以提供竞争优势。市场的本质是动态的，受到科学进步和不断增加的以患者为中心的方法的推动。因此，公司需要保持敏捷并密切监控监管变化和技术进步，以捕捉潜在的市场变化。认识到整体、有针对性的治疗的重要性并促进跨部门合作对于抓住发炎治疗市场的未来成长机会至关重要。

主要市场统计
基准年[2023] 1015.3亿美元
预测年份 [2024] 1038.5亿美元
预测年份 [2030] 1422.1亿美元
复合年增长率（%） 4.93%

市场动态：揭示快速发展的发炎治疗市场的关键市场洞察

供需的动态交互作用正在改变发炎治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球慢性病盛行率
    • 增加治疗发炎疾病的生技药品的可用性
    • 政府不断采取措施提高人们对发炎治疗的认识
  • 市场限制因素
    • 与发炎治疗相关的高成本
  • 市场机会
    • 活性化发炎治疗的研发
    • 发炎治疗的核准流程不断增加
  • 市场问题
    • 与发炎治疗相关的某些副作用

波特五力：开拓发炎治疗市场的策略工具

波特的五力框架是了解发炎治疗市场竞争格局的关键工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解发炎治疗市场的外部影响

外部宏观环境因素在塑造发炎治疗市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解发炎治疗市场的竞争格局

发炎治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：发炎治疗市场供应商的绩效评估

FPNV定位矩阵是评估发炎治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製发炎治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，发炎治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球慢性病盛行率高
      • 增加治疗发炎疾病的生技药品的可用性
      • 政府加大力度提高发炎治疗意识
    • 抑制因素
      • 与发炎治疗相关的高成本
    • 机会
      • 扩大发炎治疗的研发活动
      • 发炎治疗的核准流程增加
    • 任务
      • 与发炎治疗相关的某些副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章发炎治疗市场：依药物类别

  • 介绍
  • 发炎生技药品
  • 皮质类固醇
  • 非类固醇消炎剂(NSAID)

第七章发炎治疗市场：依适应症分类

  • 介绍
  • 抗发发炎性肠道疾病
  • 关节炎
  • 多发性硬化症
  • 干癣
  • 呼吸系统疾病

第八章发炎治疗市场：依应用分类

  • 介绍
  • 自体免疫
  • 发炎疾病
  • 呼吸系统疾病

第九章美洲发炎治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太发炎治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲发炎治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbvie, Inc.
  • Algen Healthcare Ltd.
  • Allegiant Health
  • Alvogen
  • Amgen Inc.
  • Amneal Pharmaceuticals LLC
  • Arcutis BIoTherapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Clearsynth Labs Limited
  • Genentech, Inc. by Roche Group
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Kymera Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Pharbest Pharmaceuticals, Inc.
  • Sanofi Group
  • Spectrum Chemical Mfg. Corp.
  • Sun Pharmaceutical Industries Ltd.
  • Teikoku Seiyaku Co., Ltd.
Product Code: MRR-5C6F41F5B03B

The Anti-Inflammatory Therapeutics Market was valued at USD 101.53 billion in 2023, expected to reach USD 103.85 billion in 2024, and is projected to grow at a CAGR of 4.93%, to USD 142.21 billion by 2030.

The anti-inflammatory therapeutics market encompasses treatments designed to alleviate inflammation, a common pathway in numerous diseases, including arthritis, asthma, and inflammatory bowel diseases. The burgeoning demand is fueled by an aging population, increasing prevalence of chronic diseases, and heightened awareness of the benefits of early intervention in inflammatory conditions. Anti-inflammatory therapeutics are essential in modern medicine, offering applications in pharmaceuticals, biologics, and biosimilars, with end-users ranging from hospitals and clinics to research institutes. Growth in this market is significantly influenced by advancements in biotechnology, the introduction of novel therapeutic methods, and the increasing investment in healthcare infrastructure globally. Personalized medicine and targeted therapies provide an emerging opportunity, promising enhanced efficacy and reduced side effects. The biopharmaceutical sector, supported by favorable regulatory frameworks and expedited drug approval processes in key regions, remains a fertile ground for innovation and research. Despite these opportunities, the market faces challenges such as high R&D costs, strict regulatory requirements, and the potential for adverse drug reactions, which can impede market entry and development. Furthermore, competition from generic drugs and alternative medicine poses a threat to market expansion. For sustainable business growth, companies should focus on innovative approaches like AI-driven drug discovery and the development of biosimilars. Additionally, forming strategic alliances and investing in emerging economies could offer competitive advantages. The nature of the market is dynamic, fueled by scientific advancements and increasing patient-centric approaches. Therefore, businesses should be agile, closely monitoring regulatory changes and technological advancements to seize potential market shifts. Recognizing the importance of holistic, evidence-based treatments, and fostering cross-disciplinary collaborations will be crucial for capturing future growth opportunities in the anti-inflammatory therapeutics market.

KEY MARKET STATISTICS
Base Year [2023] USD 101.53 billion
Estimated Year [2024] USD 103.85 billion
Forecast Year [2030] USD 142.21 billion
CAGR (%) 4.93%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Inflammatory Therapeutics Market

The Anti-Inflammatory Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High prevalence of chronic disorders globally
    • Rising availability of biologic drugs for the treatment of inflammatory conditions
    • Growing government initiatives to expand the awareness of inflammatory therapeutics
  • Market Restraints
    • High cost associated with anti-inflammatory therapeutics
  • Market Opportunities
    • Growing research & development activities to develop anti-inflammatory therapeutics
    • Rising approval process for anti-inflammatory therapeutics
  • Market Challenges
    • Certain side effects associated with anti-inflammatory therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Inflammatory Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Inflammatory Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Inflammatory Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Inflammatory Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Inflammatory Therapeutics Market

A detailed market share analysis in the Anti-Inflammatory Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Inflammatory Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Inflammatory Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Inflammatory Therapeutics Market

A strategic analysis of the Anti-Inflammatory Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Inflammatory Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Algen Healthcare Ltd., Allegiant Health, Alvogen, Amgen Inc., Amneal Pharmaceuticals LLC, Arcutis Biotherapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Clearsynth Labs Limited, Genentech, Inc. by Roche Group, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Kymera Therapeutics, Novartis AG, Pfizer Inc., Pharbest Pharmaceuticals, Inc., Sanofi Group, Spectrum Chemical Mfg. Corp., Sun Pharmaceutical Industries Ltd., and Teikoku Seiyaku Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Anti-Inflammatory Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Anti-inflammatory Biologics, Corticosteroids, and Non-steroidal Anti-inflammatory Drugs (NSAIDs).
  • Based on Indication, market is studied across Anti-inflammatory Bowel Disease, Arthritis, Multiple Sclerosis, Psoriasis, and Respiratory Disease.
  • Based on Application, market is studied across Autoimmune, Inflammatory Diseases, and Respiratory Diseases.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High prevalence of chronic disorders globally
      • 5.1.1.2. Rising availability of biologic drugs for the treatment of inflammatory conditions
      • 5.1.1.3. Growing government initiatives to expand the awareness of inflammatory therapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with anti-inflammatory therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing research & development activities to develop anti-inflammatory therapeutics
      • 5.1.3.2. Rising approval process for anti-inflammatory therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Certain side effects associated with anti-inflammatory therapeutics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Inflammatory Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-inflammatory Biologics
  • 6.3. Corticosteroids
  • 6.4. Non-steroidal Anti-inflammatory Drugs (NSAIDs)

7. Anti-Inflammatory Therapeutics Market, by Indication

  • 7.1. Introduction
  • 7.2. Anti-inflammatory Bowel Disease
  • 7.3. Arthritis
  • 7.4. Multiple Sclerosis
  • 7.5. Psoriasis
  • 7.6. Respiratory Disease

8. Anti-Inflammatory Therapeutics Market, by Application

  • 8.1. Introduction
  • 8.2. Autoimmune
  • 8.3. Inflammatory Diseases
  • 8.4. Respiratory Diseases

9. Americas Anti-Inflammatory Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Anti-Inflammatory Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Anti-Inflammatory Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie, Inc.
  • 2. Algen Healthcare Ltd.
  • 3. Allegiant Health
  • 4. Alvogen
  • 5. Amgen Inc.
  • 6. Amneal Pharmaceuticals LLC
  • 7. Arcutis Biotherapeutics, Inc.
  • 8. Astellas Pharma Inc.
  • 9. AstraZeneca PLC
  • 10. Bayer AG
  • 11. Bristol-Myers Squibb Company
  • 12. Clearsynth Labs Limited
  • 13. Genentech, Inc. by Roche Group
  • 14. GlaxoSmithKline PLC
  • 15. Johnson & Johnson Services, Inc.
  • 16. Kymera Therapeutics
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Pharbest Pharmaceuticals, Inc.
  • 20. Sanofi Group
  • 21. Spectrum Chemical Mfg. Corp.
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. Teikoku Seiyaku Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTI-INFLAMMATORY THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANTI-INFLAMMATORY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANTI-INFLAMMATORY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-INFLAMMATORY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-INFLAMMATORY THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RESPIRATORY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. ANTI-INFLAMMATORY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. ANTI-INFLAMMATORY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023